Drugs / Atuliflapon
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT04734275 | Feb → Mar 2021 | chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04492709 | Jul → Oct 2020 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04210388 | Jan → Mar 2020 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04087187 | Sep → Oct 2019 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03948451 | Apr → Jul 2019 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03420092 | Feb → Apr 2018 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03400488 | Jan → Jun 2018 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02963116 | Dec 2016 → Mar 2017 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02632526 | Feb → Aug 2016 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05251259 | Jan 2022 → Jan 2026 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT04601467 | Jul 2021 → May 2024 | acute coronary syndrome | National University Heart Centre, Singapore | Terminated | No outcome recorded |
| Phase 2 | NCT04492722 | Oct 2020 → Sep 2022 | chronic kidney disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT03317002 | Oct 2017 → Apr 2020 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atuliflapon | “Patients with an acute myocardial infarction (AMI) were randomized in a ratio of 1:1 ratio to receive AZD5718 (Atuliflapon) 125 mg or placebo for 12 months to assess the...” NCT04601467 ↗ |
| Known as | AZD5718 | “3 Doses of AZD5718” NCT04087187 ↗ |
| Action | Inhibit | “AZD5718 is a FLAP inhibitor that dose-dependently reduced leukotriene biosynthesis in a first-in-human study.” PMID 31793171 ↗ Dec 2019 |
| Modality | Small molecule | “AZD5718 is a first-in-class small-molecule anti-inflammatory drug” PMID 31793171 ↗ Dec 2019 |
| Route | Oral | “Oral suspension single dose” NCT02632526 ↗ |
| Target | ALOX5AP | “5-lipoxygenase-activating protein inhibitor AZD5718” PMID 35842004 ↗ Jul 2022 |